Doktor axborotnomasi 2022, №3 (106)
Subject of the article
ДИАГНОСТИКA И ТАКТИЧЕСКОЕ ВЕДЕНИЕ МИОКАРДИТА У БЕРЕМЕННЫХ (129-138)
Authors
К. Н. Абдуллажанова, З. М. Абдурахманов
Institution
Республиканский специализированный научно-практический медицинский центр акушерства и гинекологии, Ташкент, Узбекистан; Бухарский государственный медицинский институт, Бухара, Узбекистан
Abstract
Одним из важнейших и нерешенных вопросов современной гинекологии является разработка способов диагностики, ведения и прогнозирования течения миокардита у беременных. В данной обзорной статье представлены эпидемиологические данные, современное представление о патогенезе, методах диагностики и тактике ведения миокардита в сравнении с перипартальной кардиомиопатией у беременных.
Key words
миокардит, сердечная недостаточность, левый желудочек, перипартальная кардиомиопатия.
Literature
1. Aretz, H.T., Billingham, M.E., Edwards, W.D. et al. (1985). Myocarditis: a histopathologic definition and classification. Am J Cardiol Pathol 1: 1–10. 2. Baughman, K.L. and Wynne, J. (2005). Myocarditis. In: Braunwald’s Heart Disease, 7e (ed. D.P. Zipes, P. Libby, R.O. Bonow and E. Braunwald), 13597. Phyladelphia, PA: Elsvier Saunders. 3. Bohnen, S., Radunski, U.K., Lund, G.K. et al. (2015). Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 8: 1–7. 4. Bultmann B.D., Klingel K., Nabauer M., et al. (2005). High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 193: 363–365. 5. Caforio A.L., Pankuweit S., Arbustini E. et al., and European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2013). Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34: 2636–2648. 6. Caforio, A.L.P. (2013). Foreword to special issue on “Myocarditis”. Heart Fail Rev 18: 669–671. 7. Chen H.F., Lee C.N., Huang G.D., et al. (1994). Delayed maternal death after perimortem cesarean section. Acta Obstet Gynecol Scand 73: 839– 841. 8. Ciccone M.M., Dentamaro I., Carbonara S. et al. (2016). Fulminant peripartum myocarditis associated with sudden cardiac death: a case report. Cardiovasc Pathol 25: 87–89. 9. Cooper, L.T., Berry, G.J., and Shabetai, R. (1997). Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med 336: 1860–1866. 10. Cooper L.T. and Knowlton K.U. (2015). Myocarditis. In: Braunwald’s’s Heart Disease, 10e (ed. D.L. Mann, D.P. Zipes, P. Libby, et al.), 1589–1602. Phyladelphia, PA: Elsvier Saunders. 11. Cooper L. Jr., Keren A., Sliwa K. et al. (2014). The global burden of myocarditis: Part 1: A systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Global Heart 9: 121– 129. 12. Dec, G.W. Jr., Waldman, H., Southern, J. et al. (1992). Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol 20: 85–89. 13. Dennert, R., Crijns, H.J., and Heymans, S. (2008). Acute viral myocarditis. Eur Heart J 29: 2073–2082. 14. Duncker, D., Haghikia, A., Konig, T. et al. (2014). Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16 (12): 1331–1336. 15. Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008; 29: 270–276. 16. Emdin, M., Vittorini, S., Passino, C., and Clerico, A. (2009). Old and new biomarkers of heart failure. Eur J Heart Fail 11: 331–335. 17. Ergaz Z. and Ornoy A. (2006). Review: parvovirus B19 in pregnancy. Reprod Toxicol 21: 421–435. 18. Escher F., Kuhl U., Lassner D. ¨ et al. (2016). Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 105: 1011–1020. 19. Friedrich, M.G., Sechtem, U., Schulz-Menger, J. et al., and International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis (2009). Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 53: 1475–1487. 20. Frustaci, A., Russo, M.A., and Chimenti, C. (2009). Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30: 1995–2002. 21. Grun, S., Schumm, J., Greulich, S. ¨ et al. (2012). Long-term follow-up of biopsy-proven viral myocarditis: predic-tors of mortality and incomplete recovery. J Am Coll Cardiol 59: 1604–1615. 22. Grimes D.A. and Cates W. Jr. (1980). Fatal myocarditis associated with abortion in early pregnancy. South Med J 73: 236–238. 23. Gehrke D., Herzum M., Schonian U., et al. (1994). Eosinophilic endomyocarditis postpartum or pregnancy related cardiornyopathy. Herz 19: 176–181. 24. Hinojar, R., Foote, L., Arroyo Ucar, E. et al. (2015). Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging 8: 37–46. 25. Japanese Circulation Society (JCS) Joint Working Group (2011). Guidelines for diagnosis and treatment of myocarditis (JCS 2009). Circ J 75: 734–743. 26. Kindermann, I., Kindermann, M., Kandolf, R. et al. (2008). Predictors of outcome in patients with suspected myocarditis. Circulation 118: 639–648. 27. Kim, J.S., Judson, M.A., Donnino, R. et al. (2009). Cardiac sarcoidosis. Am Heart J 157: 9–21. 28. Kuhl U., Pauschinger M., Noutsias M., et al. (2005). High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘Idiopathic’ left ventricular dysfunction. Circulation 111: 887–893. 29. Kuhl, U., Lauer, B., Souvatzoglu, M., et al. (1998). Antimyosin scintigraphy and immunohistologic analysis of endomyocardial biopsy in patients with clinically suspected myocarditis – evidence of myocardial cell damage and inflammation in the absence of histologic signs of myocarditis. J Am Coll Cardiol 32: 1371–1376. 30. Kuhl, U., Pauschinger, M., Seeberg, B. et al. (2005). Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112: 1965–1970. 31. Kuhl, U., Lassner, D., von Schlippenbach, J. et al. (2012). Interferon-beta improves survival in Enterovirus-associated cardiomyopathy. J Am Coll Cardiol 60: 1295–1296. 32. Liu, P.P. and Mason, J.W. (2001). Advances in the understanding of myocarditis. Circulation 104: 1076–1082. 33. Maisch, B., Ristic, A.D., Hufnagel, G., Pankuweit, S. (2002). Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 11: 112–122. 34. Malhotra G., Chua S., Kodumuri V. et al. (2016). Rare presentation of lupus myocarditis with acute heart failure-a case report. Am J Ther 6: e1952–e1955. 35. Massengill A., Rodriguez J., Cotter T., Cotter J.G. (2016). Infectious myocarditis in pregnancy: an unlikely cause of respiratory distress. Am J Obstet Gynecol 215: S846. 36. Mahfoud, F., Gartner, B., Kindermann, M. et al. (2011). Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 32: 897–903. 37. Mason, J.W., O’Connell, J.B., Herskowitz, A. et al. (1995). The myocarditis treatment trial investigators: a clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333: 269–275. 38. McCarthy, R.E. III, Boehmer, J.P., Hruban, R.H. et al. (2000). Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342: 690. 39. Meisel, S.R., Kleiner-Shochat, M., Abu Fanne, R. et al. (2019). The diagnostic value of C-reactive protein to troponin ratio for differentiation of perimyocarditis from acute myocardial infarction. J Am Coll Cardiology 73 (1 Suppl.): 263. 40. Melvin K.R., Richardson P.J., Olsen E.G., et al. (1982). Peripartum cardiomyopathy due to myocarditis. N Engl J Med 307: 731. 41. Miller, L.W., Labovitz, A.J., McBride, L.A. et al. (1988). Echocardiographic-guided endomyocardial biopsy: a 5-year experience. Circulation 78 (Suppl.): III99–III102. 42. Mitsutake, A., Nakamura, M., Inou, T. et al. (1981). Intense persistent myocardial avid technetium 99M pyrophosphate scintigraphy in acute myocarditis. Am Heart J 101: 683–684. 43. Montero, S., Aissaoui, N., Tadie, J.M. et al. (2018). Fulminant giant-cell myocarditis on mechanical circulatory support: management and outcomes of a French multicentre cohort. Int J Cardiol 253: 105– 112. 44. Noutsias, M., Pauschinger, M., Poller, W.C. et al. (2004). Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives. Expert Rev Cardiovasc Ther 2: 37–51. 45. O’Connell, J.B., Henkin, R.E., Robinson, J.A. et al. (1984). Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. Circulation 70: 58–62. 46. O’Connell J.B., Constanzo-Nordin M.R., Subramanian R., et al. (1986). Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 8: 52–56. 47. Rizeq M.N., Rickenbacher P.R., Fowler M.B., Billingham M.E. (1994). Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 74: 474–474. 48. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Soci-ety and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circula-tion. 1996; 93: 841–842. 49. Schultheiss, H.P., Piper, C., Sowade, O. et al. (2016). Betaferon in chronic viral cardiomyopathy (BICC) trial: ef-fects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 105: 763– 773. 50. Shotan, A., Widerhorn, J., Hurst, A., and Elkayam, U. (1994). Risks of converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96: 451–456. 51. Thavendiranathan, P., Walls, M., Giri, S. et al. (2012). Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging 5: 102–110. 52. van Heeswijk, R.B., De Blois, J., Kania, G. et al. (2013). Selective in vivo visualization of immune-cell infiltration in a mouse model of autoimmune myocarditis by fluorine-19 cardiac magnetic resonance. Circ Cardiovasc Imag-ing 6: 277–284. 53. Weitsman, T., Weisz, G., Keren, A., and Hasin, T. (2016). Prompt benefit of early immunosuppressive therapy in acute lymphocytic myocarditis with persistent heart failure. Clin Res Cardiol 105: 794–796. 54. Yasuda, T., Palacios, I.F., Dec, G.W. et al. (1987). Indium Ill-monoclonal antimyosin antibody imaging in the di-agnosis of acute myocarditis. Circulation 76: 306–311.